Lyell Immunopharma, Inc. logo

Lyell Immunopharma, Inc.

NASDAQ:LYEL

Overview | Financials
Company Name Lyell Immunopharma, Inc.
Symbol LYEL
Currency USD
Price 0.41
Market Cap 121,088,580
Dividend Yield 0%
52-week-range 0.39 - 2.85
Industry Biotechnology
Sector Healthcare
CEO Dr. Lynn Seely M.D., Ph.D.
Website https://www.lyell.com

An error occurred while fetching data.

About Lyell Immunopharma, Inc.

Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate

Related Stocks

NeoGenomics, Inc. logo

NeoGenomics, Inc.

NEO

7.4 USD

LeMaitre Vascular, Inc. logo

LeMaitre Vascular, Inc.

LMAT

81.5 USD

Axsome Therapeutics, Inc. logo

Axsome Therapeutics, Inc.

AXSM

105.76 USD

Crinetics Pharmaceuticals, Inc. logo

Crinetics Pharmaceuticals, Inc.

CRNX

29.95 USD

Arcutis Biotherapeutics, Inc. logo

Arcutis Biotherapeutics, Inc.

ARQT

13.76 USD

Veru Inc. logo

Veru Inc.

VERU

0.49 USD

MannKind Corporation logo

MannKind Corporation

MNKD

4.17 USD

Financials

Numbers are in millions USD

Numbers are in millions USD